公开(公告)号：US20240425496A1

公开(公告)日：2024-12-26

申请号：US18573305

申请日：2022-07-01

Applicant: Aerie Pharmaceuticals, Inc.

Inventor： David Archer Ellis ,  Heeren M. Gordhan ,  Cynthia L. Lichorowic ,  Jill M. Sturdivant ,  Mitchell A. deLong ,  Casey Kopczynski ,  Jeffrey C. White ,  Michelle Senchyna ,  David Hollander

IPC: C07D417/14 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/551 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10 ,  C07D491/107 ,  C07D498/04

Abstract: Provided herein are azetidine pyrimidine compounds. In particular, provided herein are compounds that affect the function of kinases in a cell, and that are useful as therapeutic agents or with therapeutic agents. The compounds provided herein are useful in the treatment of a variety of diseases and conditions including inflammatory eye diseases such as uveitis, cardiovascular diseases, inflammatory diseases, and diseases characterized by abnormal growth, such as cancers. Also provided herein are compositions comprising azetidine pyrimidine compounds.

公开(公告)号：US20230149387A1

公开(公告)日：2023-05-18

申请号：US17917853

申请日：2021-04-08

Applicant: Aerie Pharmaceuticals, Inc.

Inventor： Mitchell A. deLong ,  Kevin Stephen Carbajal

IPC: A61K31/472 ,  A61K31/4439 ,  A61K33/22 ,  A61K47/18 ,  A61K47/26 ,  A61K47/10 ,  A61K31/519 ,  A61K47/02 ,  A61K9/00 ,  A61P31/14 ,  A61P27/02 ,  A61P11/00 ,  A61K31/4725

CPC classification number: A61K31/472 ,  A61K31/4439 ,  A61K33/22 ,  A61K47/183 ,  A61K47/26 ,  A61K47/186 ,  A61K47/10 ,  A61K31/519 ,  A61K47/02 ,  A61K9/008 ,  A61K9/0048 ,  A61P31/14 ,  A61P27/02 ,  A61P11/00 ,  A61K31/4725

Abstract: Described herein are compounds, combinations of compounds, compositions, formulations, and methods of treating viruses, viral load, and manifestations of viral infections.

公开(公告)号：US20210363141A1

公开(公告)日：2021-11-25

申请号：US17243272

申请日：2021-04-28

Applicant: Aerie Pharmaceuticals, Inc.

Inventor： Mitchell A. deLong ,  Jill Marie Sturdivant ,  Susan M. Royalty

IPC: C07D417/12 ,  C07C237/20 ,  C07D401/12 ,  C07D409/12 ,  C07D217/00 ,  C07C237/42 ,  C07D333/40 ,  C07D217/04 ,  C07D217/02 ,  C07D217/22 ,  C07D217/24 ,  C07D405/12 ,  C07D413/12 ,  C07D333/38

Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.

公开(公告)号：US20210300874A1

公开(公告)日：2021-09-30

申请号：US17339828

申请日：2021-06-04

Applicant: Aerie Pharmaceuticals, Inc.

Inventor： Mitchell A. deLong ,  Eric Carlson ,  Casey Kopczynski ,  Jill M. Sturdivant ,  Cynthia Lichorowic

IPC: C07D217/22 ,  A61K47/28

Abstract: Provided herein are compounds and pharmaceutical compositions useful in modulating kinase activity, and related diseases. Also provided herein are methods of treating an eye disease or disorder in a subject. Also provided herein are methods of reducing intraocular pressure in a subject. Also provided herein are methods of modulating kinase activity in a cell. Also provided herein are methods of making the compounds provided herein, and compounds useful for the preparation of the compounds provided herein.

公开(公告)号：US11028081B2

公开(公告)日：2021-06-08

申请号：US16730058

申请日：2019-12-30

Applicant: Aerie Pharmaceuticals, Inc.

Inventor： Mitchell A. deLong ,  Jill Marie Sturdivant ,  Susan M. Royalty

IPC: C07D417/12 ,  C07C237/20 ,  C07D401/12 ,  C07D409/12 ,  C07D217/00 ,  C07C237/42 ,  C07D333/40 ,  C07D217/04 ,  C07D217/02 ,  C07D217/22 ,  C07D217/24 ,  C07D405/12 ,  C07D413/12 ,  C07D333/38

Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.

公开(公告)号：US20200181090A1

公开(公告)日：2020-06-11

申请号：US16680359

申请日：2019-11-11

Applicant: Aerie Pharmaceuticals, Inc.

Inventor： Mitchell A. deLong ,  Susan M. Royalty ,  Jill Marie Sturdivant ,  Geoffrey Richard Heintzelman

IPC: C07D217/02 ,  C07D215/38 ,  C07D217/04 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12

Abstract: 6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.

公开(公告)号：US20180333405A1

公开(公告)日：2018-11-22

申请号：US15901361

申请日：2018-02-21

Applicant: Aerie Pharmaceuticals, Inc.

Inventor： Casey Kopczynski ,  Cheng-Wen Lin ,  Jill Marie Sturdivant ,  Mitchell A. deLong

IPC: A61K31/472 ,  A61K31/4725 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/559 ,  A61K9/08 ,  A61K9/00 ,  C07D217/22 ,  C07D409/12 ,  A61K47/55 ,  A61K47/54

Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

公开(公告)号：US09849122B2

公开(公告)日：2017-12-26

申请号：US15142461

申请日：2016-04-29

Applicant: Aerie Pharmaceuticals, Inc.

Inventor： Casey Kopczynski ,  Cheng-Wen Lin ,  Jill Marie Sturdivant ,  Mitchell A. deLong

IPC: C07D217/22 ,  A61K31/472 ,  A61K31/4725 ,  C07D409/12 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/559 ,  A61K9/00 ,  A61K9/08 ,  A61K47/48

CPC classification number: A61K31/472 ,  A61K9/0048 ,  A61K9/08 ,  A61K31/4725 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/559 ,  A61K47/54 ,  A61K47/55 ,  C07D217/22 ,  C07D409/12 ,  A61K2300/00

Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

公开(公告)号：US09840468B1

公开(公告)日：2017-12-12

申请号：US15395068

申请日：2016-12-30

Applicant: Aerie Pharmaceuticals, Inc.

Inventor： Gilles Chambournier ,  Mitchell A. deLong

IPC: C07D217/02 ,  C07D217/22

CPC classification number: C07D217/02 ,  C07C201/12 ,  C07D217/22 ,  C07C205/57

Abstract: Described are methods for the preparation of 6-aminoisoquinoline, a useful intermediate compound in the synthesis of kinase inhibitors.

公开(公告)号：US09365518B2

公开(公告)日：2016-06-14

申请号：US14583439

申请日：2014-12-26

Applicant: Aerie Pharmaceuticals, Inc.

Inventor： Mitchell A. deLong ,  Susan M. Royalty ,  Jill Marie Sturdivant ,  Geoffrey Richard Heintzelman

IPC: C07D217/02 ,  C07D215/38 ,  C07D401/02 ,  A61K31/47 ,  C07D217/04 ,  C07D401/12

CPC classification number: C07D217/02 ,  C07D215/38 ,  C07D217/04 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12

Abstract: 6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.